QTTB – q32 bio inc. (US:NASDAQ)

News

Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $90.00 price target on the stock.
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 [Yahoo! Finance]
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Q32 Bio to Participate in Upcoming September Investor Conferences
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com